Eli Lilly and Company

Ana Belen Bueno Melendo

Francisco Javier Agejas-Chicharro

James R McCarthy

Alan M Warshawsky

Peter Rudolph Manninen

Michael James Genin

Maria Rosario Gonzalez-Garcia

James Allen Monn

Timothy Alan Shepherd

Kumiko Takeuchi

Jeffry Bernard Franciskovich

Michael Gregory Bell

Tianwei Ma

Andrew Caerwyn Williams

Concepcion Pedregal Tercero

Nicholas Paul Camp

Anne H Dantzig

Quanrong Shen

Maria Angeles Martinez-Grau

Robert Dean Dally

Ryan Edward Stites

Jeremy Gilmore

Concepcion Pedregal-Tercero

Patric James Hahn

Peter Ambrose Lander

Todd Jonathan Kohn

Lindsay Stelzer

Stephanie Ann Sweetana

Timothy Barrett Durham

Bin Liu

Carlos Lamas-Peteira

Alfonso De Dios

Kenneth James Henry, Jr

Luisa Maria Martin-Cabrejas

Beatriz Lopez De Uralde Garmendia

Jose Alfredo Martin

Robert Anthony Doti

Carlos Montero Salgado

Jason Matthew Ochoada

Jon Andre Erickson

Graham Henry Timms

David Gene Barrett

Ivan Collado Cano

Alicia Marcos Llorente

Shu-Hui Chen

Carmen Dominguez-Fernandez

Howard Barff Broughton

Javier Agejas-Chicharro

Marc Francis Herin

Maria Rosario Gonzalez Garcia

Lindsay Scott Stelzer

GPR119 agonist compounds of the formula: and pharmaceutical compositions for the treatment of diabetes and obesity.

GPR119 agonists

Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia. 

Compounds and methods for modulating FXR

A compound of the formula: and pharmaceutical compositions for the treatment of diabetes.

Cyclopropyl compounds

Compounds of formula and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. 

Compounds and methods for modulating FX-receptors

The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation. 

3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors

The present invention provides BACE inhibitors of Formula (I): methods for their use, and intermediates and methods for their preparation. 

Amides as BACE inhibitors

This invention relates to compounds of formula (I) where Rto R, &#x2014;W&#x2014;V&#x2014;, &#x2014;X&#x2014;Y&#x2014;, p and n have the values defined in claim, their preparation and use as pharmaceuticals for the treatment of central nervous system disorders, such as depression, bipolar disorder, and anxiety.

Isochroman compounds for treatment of CNS disorders

This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.

Prodrugs of excitatory amino acids

Compounds of formula (I) in which R is halo-C alkyl; halo-C alkenyl; or (CH ) Y in which n is 1 or 2 and Y is OH, CN, N , OR , SH, S(O) R , S(O) H, NH , NHR , NR R , NHCOR , NO , CO H, CONHR , 1H-tetrazol-5-yl, 5-phenyltetrazol-2-yl or PO H ; R , R , R , R , R and R are each selected independently from C alkyl, aryl and aryl-C alkyl; R is selected from C alkyl, aryl, aryl-C alkyl, and 1H-tetrazol-5-yl, carboxy-(1-4C)alkyl and 1H-tetrazol-5-yl-C alkyl; and p is 0, 1, 2 or 3; or a salt or ester thereof, provided that R is not methoxymethyl, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system.

Excitatory amino acid receptor modulators

Growing community of inventors

Madrid, Spain

Ana Belen Bueno Melendo